Résumé
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m2 in the dexrazoxane group and 266.1+/-75.0 mg/m2 in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors.
Sujets)
Adolescent , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Mâle , Antibiotiques antinéoplasiques/effets indésirables , Cardiomyopathies/induit chimiquement , Agents cardiovasculaires/usage thérapeutique , Études de cohortes , Survie sans rechute , Doxorubicine/effets indésirables , Échocardiographie , Études de suivi , Défaillance cardiaque/induit chimiquement , Tumeurs/traitement médicamenteux , Razoxane/usage thérapeutique , Fonction ventriculaire gauche/physiologieSujets)
Humains , Amsacrine/usage thérapeutique , Vaccin BCG/usage thérapeutique , Cisplatine/usage thérapeutique , Tumeurs du côlon/traitement médicamenteux , Étoposide/usage thérapeutique , Fluorouracil/usage thérapeutique , Interféron alpha/usage thérapeutique , Interleukine-2/usage thérapeutique , Leucovorine/usage thérapeutique , Méthotrexate/usage thérapeutique , Mitomycines/usage thérapeutique , Razoxane/usage thérapeutique , Sémustine/usage thérapeutique , Streptozocine/usage thérapeutique , Tamoxifène/usage thérapeutique , Tioguanine/usage thérapeutique , Vincristine/usage thérapeutique , Chloro-éthylène/usage thérapeutiqueRésumé
Se describe la experiencia clínica con el uso de Razoxone ICRF 159, una nueva droga antitumoral, en el tratamiento de 57 pacientes con formas severas de psoriasis. Esta medicación demostró ser efectiva sobre todo en las formas generalizadas eritrodérmicas y con compromisos articulares. Es bien tolerada y parece estar libre de hepatotoxicidad; sin embargo puede producir depresión medular, efecto que está directamente relacionado con la dosis. Se investigó su asociación con teleroentgenterapia por su propiedad radiopotenciadora